PR

Progesterone receptor (PR) is a member of the steroid hormone receptor family. Its binding to progesterone can regulate the growth and development of various organs such as breast, uterus, ovary, and placenta, which will maintain the normal function of the reproductive system. Oncological research found that PR is expressed in about 70% of breast cancer, which depends on the positive regulation mediated by the binding of estrogen and its receptor (ER). Meanwhile, some studies have shown that estrogen can promote the proliferation and metastasis of cancer cells, but endocrine therapy drugs can inhibit tumor growth by inhibiting estrogen production or blocking estrogen binding to ER. Therefore, the positive expression of PR, which is considered to be the signal of estrogen binding to ER, is closely related to the good prognosis of patients. In summary, the combination of PR and ER has important clinical significance for the diagnosis, treatment, and prognosis of breast cancer, endometrial cancer and other cancers. However, the relationship between PR and tumor growth is currently inconclusive.